Pharmaceutical manufacturing has had to navigate transformational changes during the pandemic, just like many other industrial sectors. Demand for manufacturing capacity reached levels that would have been unthinkable a few short years ago.
Yet although the situation was unprecedented, and the measures taken extraordinary, the pandemic did not actually change the direction of travel for how biopharma companies manufacture drugs.
As biotherapeutics rapidly evolve and diversify, manufacturing needs to do the same, particularly regarding how and where drugs are produced. The traditional monoliths of large, centralized facilities need to be augmented with a constellation of smaller, more flexible ones to support the exciting new modalities made mainstream by the pandemic.
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
To submit a correction request, please visit our Contact Us page.
